Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment

Fig. 1

a Change in representative omental metastasis on CT scan after treatment with durvalumab- tremelimumab on Day 1. Arrows indicate omental metastasis replaced by fatty tissue. Scale bar indicates 25 mm. b Clinical course of patient until death from neuromuscular respiratory failure on Day 65. Serum CO2 retention is indicative of hypoventilation

Back to article page